Search the Newsreel

Scully Royalty names interim CEO and CFO as chairman steps in during leadership search

Scully Royalty Ltd. has appointed Chairman Michael Smith as interim CEO and CFO, replacing Samuel Morrow, who will remain a non-executive director. Smith will oversee executive functions while the company searches for permanent leadership. The company has committed to maintaining disciplined financial oversight during …

Clever Culture Systems Seeks ASX Quotation for 2.6 Million New Shares

Is 4D Molecular Therapeutics Inc (FDMT) Undervalued After Q2 Ear

4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results

Moleculin Biotech (NASDAQ: MBRX) advances AML trial but warns on cash

Moleculin Biotech (NASDAQ: MBRX) is progressing with its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed/refractory AML, showing promising preliminary efficacy and cardiac safety data. Despite these clinical advancements and a recent $9.3 million equity/warrant offering, the company reported a net loss of …

Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Moleculin Biotech, Inc. reported its Q2 2026 financial results, highlighting significant progress in its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed/refractory AML. Interim results showed complete remission rates three times higher than the control arm, with continued absence of cardiotoxicity. The company …

4D Molecular Therapeutics (FDMT) posts $141.7M first-half 2026 net loss

FDMT (NASDAQ: FDMT) stockholder schedules 1,635-share sale after option exercise

A stockholder of 4D Molecular Therapeutics, Inc. (FDMT) has filed to sell 1,635 common shares on NASDAQ, to be issued through the exercise of stock options for cash on August 13, 2026. This filing also discloses previous Rule 10b5-1 plan sales by Scott Bizily …

4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4D Molecular Therapeutics (4DMT) reported its Q2 2026 financial results, highlighting significant progress in its clinical programs for wet AMD and DME, including completed enrollment for two Phase 3 trials for 4D-150 and strong two-year data from its PRISM Phase 2b study. The company …

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. announced inducement grants to Ms. Beth Rada, the new SVP of Government Affairs and Public Policy. These awards, consisting of stock options and restricted stock units, were granted under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule …

Ocular Therapeutix’s New Policy Leader Gets an 85,000-Share Option

Ocular Therapeutix (NASDAQ: OCUL) has granted its new SVP, Government Affairs and Public Policy, Beth Rada, inducement equity awards under its 2019 Inducement Stock Incentive Plan. These awards, effective August 10, 2026, include a non-statutory option to purchase up to 85,000 shares at $9.24 …

4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) reported a Q2 loss of $1.04 per share, matching Zacks Consensus Estimate, but surpassed revenue estimates significantly with $3.78 million, beating expectations by 142.37%. The company's stock has performed well year-to-date, rising 58.3% against the S&P 500's 13.2% gain, …

Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy met its primary endpoint of progression-free survival in patients with first-line EGFR exon 20 insertion mutation non-small cell lung cancer. The study showed a statistically significant …

How Investors May Respond To LeMaitre Vascular (LMAT) Trimmed 2026 Outlook Despite Higher Q2 Sales

LeMaitre Vascular (LMAT) reported higher Q2 2026 sales and net income, but trimmed its full-year 2026 outlook due to currency headwinds, Middle East export delays, and cardiac allograft supply constraints. Despite these challenges, the company reinforced its growth narrative, though the revised guidance highlights …

GEHC or LMAT: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. There are plenty of strategies …

AirSculpt Technologies, Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now

AirSculpt Technologies (NASDAQ: AIRS) shares dropped 34% after missing second-quarter revenue predictions and reporting a statutory loss. Analysts have since increased loss per share expectations for 2026 and significantly cut the average price target, signaling concerns about growing losses and slower revenue growth compared …

Molecular Partners AG (MOLNZ.XC) stock price, news, quote and history

LeMaitre Vascular remains a Buy despite 31% pullback; strong organic growth and record margins support outlook.

LeMaitre Vascular's stock experienced a 31% drop after missing Q2 2026 expectations due to currency issues, export blockages, and tissue shortages. However, the company demonstrates strong underlying demand with 10% organic sales growth and record-high margins, driven by its fastest-growing product, Artegraft. Despite the …

LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut (NASDAQ:LMAT)

Federal Agricultural Mortgage Corporation (NYSE:AGM) Plans $1.60 Quarterly Dividend

Scully Royalty Ltd. Provides Corporate Update

Scully Royalty Ltd. announced that its Chairman, Michael Smith, has been appointed interim Chief Executive Officer and Chief Financial Officer, replacing Samuel Morrow, who will now serve as a non-executive director. Mr. Smith will lead the company while it searches for permanent candidates for …

Why is Cullinan Oncology stock surging today? By Investing.com

Ocular Therapeutix (OCUL) Posts Wider Losses And Files Shelf Registration, Is It Still Undervalued?

Ocular Therapeutix (OCUL) is under investor scrutiny following wider quarterly losses and a new shelf registration filing, which could lead to future stock dilution. Despite a recent share price rebound, the stock remains down year-to-date. The company's valuation is heavily tied to the potential …

OCUL Stock In Spotlight After Q2 Loss Comes In Narrower Than Estimated – A Look At Key Highlights

The Top 5 Analyst Questions From LeMaitre’s Q2 Earnings Call

The Top 5 Analyst Questions From LeMaitre's Q2 Earnings Call LeMaitre's second quarter was marked by strong organic revenue gains, led by robust growth in its Artegraft line and continued expansion across Europe and Asia. However, the quarter fell short of Wall Street's revenue …

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Report Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial in First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for zipalertinib combined with chemotherapy in first-line EGFR exon 20 insertion mutation non-small cell lung …

Australian Agricultural Company (ASX:AAC) Shares Slip Into Red Territory as Investors Watch Beef Market Trends

Cullinan, Taiho's Zipalertinib - Chemotherapy Combo Meets Key Goal In Phase 3 NSCLC Trial; Stock Up

(RTTNews) - Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (CGEM) announced that the Phase 3 REZILIENT3 trial, evaluating the combination of zipalertinib and platinum-based chemotherapy in the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), met …

Stronger NII And Buybacks Could Be A Game Changer For Cullen/Frost Bankers (CFR)

Cullen/Frost Bankers (CFR) recently reported strong second-quarter 2026 results, including higher net interest income (NII) and net income, reduced charge-offs, and a significant share repurchase program. The company also raised its full-year 2026 NII and margin guidance, signaling management's confidence. This performance supports the …

AirSculpt Technologies (AIRS): Vesey-led group reports control of 30.3M shares

A group of investors affiliated with Vesey Street Capital, led by Adam T. Feinstein, has filed an amended Schedule 13G/A, disclosing beneficial ownership of 30,324,180 shares, or 42.1%, of AirSculpt Technologies (AIRS) common stock. This ownership includes direct holdings by various Vesey-affiliated entities and …

Farmer Mac Sets Payments for Three Common, Six Preferred Classes

Farmer Mac (NYSE: AGM) has announced its third-quarter 2026 dividends. This includes a $1.60 per share dividend for all three classes of its common stock, payable on September 30, 2026, to shareholders of record as of September 15, 2026. Additionally, the company declared quarterly …

Agriculture & Natural Solutions (ANSC) moves to remove shares and warrants from Nasdaq

Agriculture & Natural Solutions Acquisition Corp (ANSC) is delisting its Class A ordinary shares, warrants, and units from the Nasdaq Stock Market LLC. This action is a voluntary withdrawal by the issuer, compliant with both Nasdaq's rules and SEC regulations under Section 12(b) of …

Agriculture & Natural Solutions Acquisition Corporation(NasdaqGM:ANSC) dropped from NASDAQ Composite Index

Agriculture & Natural Solutions Acquisition Corporation (ANSC) has been removed from the NASDAQ Composite Index. This news follows previous reports on the company's earnings, including for the first quarter ended March 31, 2026, and its auditor raising 'Going Concern' doubt in March 2026 and …

AirSculpt Sees Core Stabilization, Targets $100M-Plus GLP-1 Opportunity

AirSculpt Technologies (AIRS) is experiencing stabilization in its core body-contouring business after previous declines, attributing this to new talent and improved sales strategies. The company is also expanding into services for patients using GLP-1 weight-loss drugs, seeing a significant opportunity potentially exceeding $100 million …

AirSculpt® Partners with Tiger Aesthetics™ in First National Partnership to Offer alloClae™

AirSculpt®, a leader in minimally invasive body contouring, has announced its first national partnership with Tiger Aesthetics™ to offer alloClae™, an off-the-shelf structural adipose tissue. This collaboration aims to expand AirSculpt's body enhancement offerings, providing patients with a new treatment option for natural-looking volume …

Airsculpt Technologies(AIRS) Stock Options Chain | Quotes & News

This article provides access to the stock options chain, quotes, and news for Airsculpt Technologies (AIRS). It serves as a resource for investors looking for detailed financial information and market performance data for the company.